SRSF4

Across TCGA pan-cancer cohorts, SRSF4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SRSF4 data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher SRSF4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SRSF4 expression acts as an unfavorable survival marker.

LUSC, PRAD, and UCEC are the cancer types where SRSF4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	OS	Median	All	0.327	0.678	.009	12	view →
PRAD	DFS	Median	All	0.617	0.886	.045	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
CHOL	OS	Median	All	0.155	0.725	.029	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SRSF4–LUSC (OS)

Open the LUSC breakdown →